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Abstract 
Background: The growing burden of the HIV and non-communicable disease (NCD) syndemic in Sub- Saharan 
Africa has necessitated introduction of integrated models of care in order to leverage existing HIV care infrastructure 
for NCDs. However, there is paucity of literature on treatment outcomes for multimorbid patients attending inte-
grated care. We describe 12-month treatment outcomes among multimorbid patients attending integrated antiretro-
viral treatment (ART) and NCD clubs in Cape Town, South Africa.
Methods: As part of an integrated clubs (IC) model pilot implemented in 2016 by the local government at two 
primary health care clinics in Cape Town, we identified all multimorbid patients who were enrolled for IC for at least 
12 months by August 2017. Mean adherence percentages (using proxy of medication collection and attendance of 
club visits) and optimal disease control (defined as the proportion of participants achieving optimal blood pressure, 
glycosylated haemoglobin control and HIV viral load suppression where appropriate) were calculated at 12 months 
before, at the point of IC enrolment and 12 months after IC enrolment. Predictors of NCD control 12 months post IC 
enrolment were investigated using multivariable logistic regression.
Results: As of 31 August 2017, 247 HIV-infected patients in total had been enrolled into IC for at least 12 months. Of 
these, 221 (89.5%) had hypertension, 4 (1.6%) had diabetes mellitus and 22 (8.9%) had both diseases. Adherence was 
maintained before and after IC enrolment with mean adherence percentages of 92.2% and 94.2% respectively. HIV 
viral suppression rates were 98.6%, 99.5% and 99.4% at the three time points respectively. Retention in care was high 
with 6.9% lost to follow up at 12 months post IC enrolment. Across the 3 time-points, optimal blood pressure con-
trol was achieved in 43.1%, 58.9% and 49.4% of participants while optimal glycaemic control was achieved in 47.4%, 
87.5% and 53.3% of participants with diabetes respectively. Multivariable logistic analyses showed no independent 
variables significantly associated with NCD control.
Conclusion: Multimorbid adults living with HIV achieved high levels of HIV control in integrated HIV and NCD clubs. 
However, intensified interventions are needed to maintain NCD control in the long term.
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Background
South Africa has the world’s largest burden of HIV, 
with an HIV prevalence of 12% [1]. Consequently, it has 
the largest antiretroviral treatment (ART) program in 
the world [2], with 3.4 million patients receiving ART 
care at no cost to the individual [3]. Since the advent 
of effective ART, HIV has become a chronic, manage-
able illness, with lifespan approaching that of HIV-
negative persons [4]. This increased lifespan, along 
with the aging effect of HIV and drug interactions [5, 
6], has resulted in an increased risk of developing non-
communicable diseases (NCDs) and consequentially an 
increased burden of multimorbidity (MM) among peo-
ple living with HIV (PLHIV). Multimorbidity is defined 
as the co-existence of more than one chronic condition 
in one person [7].
Previous research has shown that there is a signifi-
cant burden of MM in South Africa with prevalence 
estimates ranging from 22.6 to 48.4% [8, 9]. A study 
investigating MM in Khayelitsha, Western Cape (the 
setting of this study), found high prevalence of comor-
bid hypertension and diabetes (19.7% and 12.3% respec-
tively) amongst PLHIV on ART aged between 18–35 
[9]. This dual epidemic of communicable and NCDs has 
knock-on effects on the current health system which 
is ill-equipped to cope with the inherent complexity of 
MM [10]. The high comorbidity among PLHIV high-
lights the need to integrate care of these conditions 
into routine ART management. In the Western Cape, 
South Africa, PLHIV without NCD diagnoses attend 
regular ART medical adherence clubs (MACs) which 
comprise 25–30 PLHIV who have been on ART for at 
least 6 months with suppressed viral loads (VL). MACs 
involve both task-shifting and decentralization of care 
at the primary health care level and have been shown to 
decongest healthcare facilities [11], improve retention 
in care [12], maintain virologic suppression [13], be 
cost effective [14] and acceptable to both patients and 
health care workers [15].
In response to the rising burden of MM, some clinics 
in the city of Cape Town have sought to achieve inte-
gration; piloting a novel model of care that adapts the 
MAC model to integrate HIV and NCD care. The struc-
ture and eligibility for HIV/NCD integrated care (IC) is 
similar to the MAC model with the eligibility criteria 
of a diagnosis of NCD such as Diabetes Mellitus (DM) 
or hypertension (HTN) or both (DMHTN) in patients 
with HIV Prior to this pilot, the standard of care for a 
MAC attendee with comorbid NCD comprised attend-
ing a MAC club for ART care and a different outpatient 
appointment for NCD care often on a different day 
and sometimes, at a different health facility. In order 
to minimize logistical barriers to accessing NCD care 
for multimorbid patients and improve efficiency of 
health care delivery, PLHIV and clinically controlled 
NCD were enrolled in new IC clubs that provide HIV 
and NCD care concurrently. Initially, in the piloting 
phase, IC club participants were recruited from ART 
only adherence clubs. Upon successful implementa-
tion of the IC club pilots, eligibility was expanding to 
include any patient with clinically controlled HIV and 
NCD diagnoses, irrespective of whether they were part 
of ART only adherence clubs. Majority (80.2%) were 
initially attending ART only adherence clubs whereas 
19.8% were enrolled from standard of care.
We have   comprehensively described various models 
of integrated HIV/NCD care that exist to date    in our 
scoping review [Duration with NCD [44]]. The models 
of care for HIV/NCD integration can be summarized 
into four as: (i) integration of NCD screening and treat-
ment services into established HIV centres [16–18]; (ii) 
integration of HIV screening and treatment services 
into established NCD centres; (iii) simultaneous inte-
gration of HIV and NCD services at health facilities 
[19–21] and (iv) integrated HIV and NCD care specifi-
cally for multi-morbid patients [22, 23]. Noteworthy is 
the fact that only two studies worldwide have reported 
treatment outcomes among PLHIV with comorbid DM 
or HTN (model iv) [22, 23], and no study has evalu-
ated treatment outcomes among PLHIV with comorbid 
NCDs attending IC in particular.
It is against this background that we sought to inves-
tigate the long term patient outcomes, among PLHIV 
with MM attending IC model of care since implementa-
tion in Cape Town. These long-term outcomes include, 
but are not limited to, medication adherence, retention 
in care, loss to follow up, HIV viral suppression and 
NCD control. Thus, it is not known if IC improves or at 
least maintains the desired clinical HIV and NCD out-
comes compared to standard of care (MAC plus sepa-
rate NCD care) in multimorbid PLHIV. Such evidence 
is needed to inform action by health program manag-
ers and policy makers in order to adopt, implement 
and scale up IC for PLHIV with NCD multimorbid-
ity, particularly in high HIV-burden settings under-
going rapid  epidemiological transition. In this study, 
Keywords: HIV/AIDS, Hypertension, Diabetes mellitus, Non-communicable diseases, Multimorbidity, Integrated care, 
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we addressed this knowledge gap by assessing clinical 
outcomes in patients with HIV and comorbid DM and/
or HTN before and after 12 months of receiving the IC 
model of care in Cape Town, South Africa.
Methods
Study setting and design
We conducted an observational retrospective cohort 
study that followed up patients living with HIV and 
comorbid NCD before and upon enrolment into inte-
grated clubs(IC). Routine clinic data were collected from 
patient medical records and club registers in order to 
assess clinical outcomes for PLHIV 12 months before, at 
the point of IC entry, and 12 months after attending IC at 
two City of Cape Town primary care clinics(clinic A and 
B, names withheld to maintain participant confidential-
ity) in Cape Town, South Africa. The two public health 
facilities are under the governance of the City of Cape 
Town Health Department and both ART and NCD treat-
ment are provided for free. They are based in the peri-
urban township of Khayelitsha which has a population of 
approximately 500,000 [24] and an estimated antenatal 
HIV prevalence of 34.3% [25]. The study was approved 
by the University of Cape Town, Faculty of Health Sci-
ences Human Research Ethics committee (HREC Ref no: 
497/2019).
Sampling and statistical power
Study participants were all adults over 18 years old, who 
had documented HIV-infection and a diagnosis of either 
DM or HTN or both, had attended MACs for HIV care 
or had been on ART for at least 6  months before they 
were enrolled into IC and had been enrolled in ICs for at 
least 12 months as of August 2017. All adult patients who 
attended IC at the two pilot sites and met these inclu-
sion criteria were included in the study. As there were a 
limited number of patients with multimorbidity attend-
ing the study clinics and no published studies that have 
investigated patient outcomes among comorbid PLHIV 
attending IC, we approached the entire population of 
adult patients who attended IC at the two pilot sites for 
consent and recruitment into the study.
Data collection
Patients with comorbid diagnosis of HTN, DM or both 
(DMHTN) were identified from the IC club registers 
and clinic folders. Diagnosis of HTN or DM was made 
by facility clinicians based on the South African Pri-
mary Care (PACK) guidelines [27]. Outcome measures 
(blood pressure (BP), VL, and glycosylated heamoglobin 
(HbA1c)) were extracted from electronic and paper clinic 
records from September 2016 to August 2017. Participant 
data were collected retrospectively from participants 
clinical records and club registers. Clinical procedures 
routinely undertaken in MAC and IC clubs are illustrated 
in Table 1. Anonymized data were captured by a trained 
study team onto a Redcap electronic database hosted at 
the University of Cape Town [28].
Patient demographic (age, sex), anthropomet-
ric (weight, height), disease-related (NCD diagnoses, 
time since NCD diagnosis, World Health Organization 
(WHO) stage at HIV diagnosis, CD4 count at HIV diag-
nosis, time since HIV diagnosis, duration on ART), and 
IC club-related (IC club registration date, IC clinic) vari-
ables were extracted. Adherence was assessed 12 months 
before and 12  months after IC enrolment. Prior to IC 
enrolment, we used medication collection as a proxy for 
adherence. After IC enrolment, adherence to club visits 
(club attendance), extracted from club registers was used 
as a proxy for adherence. Good adherence was defined as 
proportion of attended visits of > 80%, according to WHO 
classification of adherence to long term therapy [29].
Variables related to disease control were measured at 
12 months before IC enrolment, at IC enrolment and at 
12 months after IC enrolment. HIV control was defined 
as having a viral load of < 1000 copies/ml [26] whereas 
NCD control was defined by the Society of Endo-
crinology, Metabolism and Diabetes of South Africa 
(SEMSA) targets for BP (BP < 140/90 mmHg) and HbA1c 
(HbA1c < 7.5%) among persons with hypertension and 
diabetes respectively [30].
Statistical analysis
Given small numbers, participant data from both clin-
ics were pooled for analysis. Categorical variables were 
described using frequencies and proportions, normally 
distributed continuous variables using means and 95 per-
cent confidence intervals (95% CI), and non-parametric 
continuous variables using medians and interquartile 
ranges (IQR). Adherence to scheduled appointments was 
calculated as the proportion of appointments attended 
by each participant from 12  months prior to IC enrol-
ment up to the point of IC enrolment, and from IC enrol-
ment to 12  months later. Mean adherence percentages 
were calculated for the 12 months prior to IC enrolment 
and 12 months post IC enrolment and compared using a 
paired student t-test. The proportion of participants with 
optimally controlled NCDs according to SEMSA targets 
was calculated cross-sectionally for the three time points: 
(i) at 12 months before IC enrolment, (ii) at IC enrolment 
and (iii) at 12 months post IC enrolment.
The proportions of participants with optimally con-
trolled NCD at IC enrolment and at 12 months post IC 
enrolment were compared using the Chi-squared test 
under the null hypothesis that IC enrolment maintains 
clinical control of multimorbidity. Chi-square or Fish-
er’s exact tests were used where appropriate to explore 
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baseline variables associated with control of NCD at 
12  months post IC. Univariate logistic regression was 
used to explore factors associated with comorbidity con-
trol and crude odds ratios calculated to identify inde-
pendent variables that yielded a p-value of ≤ 0.2. These 
variables were used to build a multivariate logistic model 
to estimate adjusted odds ratios and 95% CI for predic-
tors of clinical control of NCD, with the outcome vari-
able (NCD control) categorised as 1 if HTN or DM or 
both, were optimally controlled at 12  months post IC 
enrolment and as 0 if otherwise. Significance testing was 
performed using 2-sided p-values at α of 0.05. All statisti-
cal analyses were conducted in STATA 15.0 (Stata Corp 
LP, College Station, TX).
Results
As of 31 August 2017, a total of 247 patients had been 
enrolled into IC clubs for at least 12 months at the two 
primary health care facilities (Table  2). There were 
no significant differences in demographic and clinical 
Table 2 Demographic and clinical characteristics of study participants at baseline
HTN Hypertension, DM Diabetes mellitus type 2, DMHTN dual diagnosis of HTN and Diabetes Mellitus type 2, NCD non-communicable disease which implies either DM 
or HTN or both in this case, SD standard deviation of the mean
a Characteristics are described as n (%) where n is number of participants with the characteristic and % is percentage of the study population with the given 
characteristic
b Cells/µL
Bold p values indicated statitistical significance
Variablea Clinic A (n = 71) Clinic B (n = 176) Total (N = 247) p-value
Age (years), mean ± SD 48.4 ± 8.4 45.9 ± 8.7 46.7 ± 8.6 0.051
Sex, male 18 (25.4) 41 (23.3) 59 (23.9) 0.865
Comorbidity
 DM only 0 (0) 4 (2.3) 4 (1.6)
 HTN only 63 (88.7) 158 (89.8) 221 (89.5)
 DM and HTN 8 (11.3) 14 (7.9) 22 (8.9) 0.326
Time with NCD (years)
 0–5 43 (60.6) 124 (70.5) 167 (67.6)
 6–10 20 (28.2) 4 (2.3) 24 (9.7)
 > 10 3 (4.2) 3 (1.7) 6 (2.4)  < 0.001
 Missing 5 (7.0) 45 (25.6) 50 (20.2)
Time with HIV (years)
 0–5 31 (43.7) 91 (51.7) 122 (49.4)
 6–10 28 (39.4) 49 (27.8) 77 (31.7)
 > 10 11 (15.5) 15 (8.5) 26 (10.5)
 Missing 1 (1.4) 21 (11.9) 22 (8.9) 0.113
Time on ART (years)
 0–5 48 (67.6) 139 (78.9) 187 (75.7)
 6–10 22 (30.9) 36 (20.5) 58 (23.5)
 > 10 1 (1.1) 1 (0.6) 2 (0.8) 0.155
WHO stage at HIV diagnosis
 0 14 (19.7) 60 (34.1) 74 (29.9)
 1 21 (29.6) 53 (30.1) 74 (29.9)
 2 28 (39.5) 43 (24.4) 71 (28.7)
 3 6 (8.5) 15 (8.5) 21 (8.5)
 4 2 (2.8) 5 (2.8) 7 (2.8) 0.103
CD4 count at HIV  diagnosisb
 < 350 40 (56.3) 89 (50.6) 129 (52.2)
 ≥ 350 25 (35.2) 42 (23.9) 67 (27.1)
 Missing 6 (8.5) 45 (25.6) 51 (20.7) 0.374
 Median CD4 count at HIV diagnosis 
(IQR)b
294 (121–419) 249 (150–393) 261.5 (146–403.5)
 HIV suppression rates 64 (90.1) 147 (83.5) 211 (85.4)
 Missing 7 (9.9) 28 (15.9) 35 (14.2) 0.627
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characteristics between patients at the two facilities 
at baseline, with the exception of duration with NCD 
(patients receiving care at Clinic B had relatively more 
recent NCD diagnoses compared to patients at Clinic A) 
(Table 2).
Patterns of multi-morbidity and treatment
Of the 247 patients, 221 (89.5%) had comorbid HTN, and 
22 (8.9%) had a triple burden of HIV, DM and HTN. Four 
(1.6%) patients had DM only. The median time with mul-
timorbidity regardless of type of NCD, was 3 (IQR (2–4) 
years among patients with available data on duration 
since NCD diagnosis (n = 197) (Table 2).
Among those with HTN, 95.5% received pharmacologi-
cal therapy. The majority of patients were being treated 
with Hydrochlorothiazide alone (82.9%), Hydrochloro-
thiazide and Enalapril (9.9%) whereas (6.6%) were treated 
with a combination of Hydrochlorothiazide, Enalapril 
and Amlodipine. All patients with comorbid DM were 
treated with oral anti-glycaemic agents. Pharmacologi-
cal therapy for HTN among patients with HTN and DM 
was similar to that among patients with HTN only (Addi-
tional file 1: Table S1).
Fig. 1 Available records for viral loads (VL), blood pressure (BP) and glycosylated heamoglobin (HbA1c) at three time points in the study. HbA1c 
measured in patients with DM
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Outcome variable measurements
Documented measurements for our outcome vari-
ables (viral load, blood pressure and HbA1c) varied at 
12 months prior to IC, IC entry and 12 months post IC. 
Figure  1 shows number and percentage of participants 
with documented outcome variable  measurements at 
the three end points. At the end of 12 months post IC, 17 
(6.9%) participants overall, were lost to follow up.
Adherence to medication
As adherence proportions before and after IC were nor-
mally distributed, a paired t-test was used to assess differ-
ences in mean adherence. Mean adherence proportions 
before and after IC enrolment were 92.2% and 94.2% 
respectively. There was no significant difference in mean 
adherence proportions before and after attending IC 
(p = 0.223) either overall or by patterns of MM.
We compared the proportion of patients with good 
adherence (adherence > 80%) before and after attending 
IC and found no difference in the percentage of patients 
with good adherence (91.9% and 90.3% respectively, 
p = 0.693).This observation did also not change when cat-
egorised by patterns of MM.
HIV control
In our study population, 215/247 (87.0%) had docu-
mented viral load testing at 12 months prior to IC enrol-
ment. Of these, 212 (98.6%) were virally suppressed. 
Similarly, 212 (85.8%) patients had documented viral load 
testing at IC enrolment and 211 (99.5%) were virally sup-
pressed. Twelve months after IC, 164 (66.4) had docu-
mented viral load testing of which 163 (99.4%) were 
virally suppressed. Of the participants enrolled in IC, 
93.1% were retained in care at 1-year post IC enrolment 
with 6.9% lost to follow up (Fig. 1). HIV control did not 
differ by patterns of MM.
Blood pressure control
Blood pressure control was assessed among all partici-
pants including those with only DM as this is part of rou-
tine clinical evaluation for comprehensive diabetes care. 
Of the 247 participants, 205 (82.9%), 212 (85.8%) and 
162 (65.6%) had blood pressure measurements at 1-year 
before IC, at IC enrolment and 1-year post IC enrolment 
respectively (Fig.  1). Among those with blood pressure 
measurement, 43.4%, had controlled BP at 1 year before 
IC, 58.9% had controlled BP at IC entry while 49.4% 
had controlled their BP at 1  year post IC enrolment. 
Mean systolic blood pressure (SBP) was 139.9  mmHg 
[95% CI (136.9–142.9  mmHg)], 132.1  mmHg (95% 
CI (129.7–134.6  mmHg)) and 136.7  mmHg [95% CI 
Fig. 2 Mean systolic blood pressure at three time points: 12 months 
before, at entry and 12 months after entry to integrated club
Fig. 3 Mean diastolic blood pressure at three time points: 12 months 
before, at entry and 12 months after entry to integrated club
Fig. 4 Mean glycosylated heamoglobin (HbA1c) at three time points: 
12 months before, at entry and 12 months after entry to integrated 
club
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(133.7–139.6  mmHg)] at these time points respectively; 
demonstrating a pattern of decrease up to the point of 
enrolment and increasing 1  year later. This pattern was 
also observed for diastolic blood pressure (DBP) with the 
mean DBP of 84.7  mmHg [95% CI (82.7–86.6  mmHg)], 
79.7 mmHg [95% CI (78.2–81.2 mmHg)] and 80.1 mmHg 
[95% CI (78.4–81.9  mmHg)] at 1-year before IC, at IC 
enrolment and 1-year post IC enrolment respectively 
(Figs. 2 and 3).
The pattern of increasing SBP at 1-year post-IC enrol-
ment compared to IC entry was statistically significant 
(p = 0.009) whereas the pattern of increasing DBP 1-year 
post-IC enrolment compared to IC entry was not statisti-
cally significant (p = 0.370).
BP control declined by 9.5% at 1-year post IC 
(p = 0.033) with 43.4% [95% CI (34.6–50.5%)], 58.9% 
[95% CI (52.0–65.7%)] and 49.4% [95% CI (41.5–57.3%)] 
of participants with optimally controlled BP at 1-year 
before IC enrolment, at IC enrolment and at 1-year post 
IC enrolment respectively (Fig. 4).
Comparing optimal BP control at 1-year post IC enrol-
ment in participants with HTN only with those with 
DM and HTN, there was no significant difference in BP 
control among the two patient groups (64.3% vs 47.6% 
respectively, p = 0.117).
Diabetes control
Of 26 patients with DM (either DM alone or DMHTN), 
19 (73.1%), 16 (61.5%) and 15 (57.7%) had recorded 
HbA1c measurement 12 months prior to IC enrolment, 
at IC enrolment and at 1-year post IC enrolment respec-
tively. Mean HbA1c among all patients with DM (either 
DM or DMHTN) was 8.9% [95% CI (7.3–10.5%)], 7.0% 
[95% CI (6.4–7.6%)], and 8.3% [95% CI (6.8–9.9%)] at 
these time points (Fig. 5). The proportion of patients with 
optimally controlled DM at 1-year post IC enrolment 
was significantly lower compared to the same propor-
tion at IC enrolment (p = 0.018) with more than 30% of 
participants who had initially achieved optimal glycae-
mic control at IC enrolment having sub-optimal glycae-
mic control 1-year following IC enrolment [47.4% (95% 
CI (24.5–71.1%)], 87.5% [95% CI (61.7–98.5)] and 53.3% 
(95% CI (26.6–78.7) at 1-year pre IC enrolment, at IC 
enrolment and at 1-year post IC enrolment respectively).
Factors associated with optimal NCD control
Three variables at baseline were significantly associ-
ated with control of NCD after 12  months of attending 
IC. These are WHO stage at baseline, time with NCD 
and facility (Table  3). Clinic A was associated with bet-
ter NCD control compared to clinic B. This could be due 
to presence of enabling health system factors at clinic A 
not available at clinic B such as well-trained club facili-
tators. Unexpectedly, patients who had a more recent 
diagnosis of NCD had better controlled disease com-
pared to patients with an earlier diagnosis. On the same 
note, women were observed to be more likely to control 
their NCD compared to men even though this associa-
tion was not statistically significant (p = 0.072). On mul-
tivariate analysis of factors associated with NCD control 
at 12 months post IC, the association between these vari-
ables and NCD control was not statistically significantly 
at α = 0.05 (Table 4).
In univariate logistic regression models, time with 
NCD, adherence status and IC clinic site at baseline 
were associated with control of NCD at α = 0.2 level 
(Table 4). However, on multivariate analysis, the associa-
tion between these variables and NCD control 12 months 
post-IC enrolment was not statistically significantly at 
α = 0.05 (Table 4).
Discussion
This is the first study to report treatment outcomes 
among PLHIV diagnosed with NCDs attending inte-
grated NCD/ ART clubs piloted in Cape Town, South 
Africa. Several studies have reported treatment out-
comes in various models of integrated HIV and NCD 
care. The models of care for HIV/NCD integration have 
been summarized before into four as: (i) integration of 
NCD screening and treatment services into established 
HIV centres [16–18]; (ii) integration of HIV screening 
and treatment services into established NCD centres; 
(iii) simultaneous integration of HIV and NCD services 
at health facilities [19–21] and (iv) integrated HIV and 
NCD care specifically for multi-morbid patients [22, 23]. 
However, none of  studies  has evaluated treatment out-
comes among PLHIV with comorbid NCDs attending IC 
in form of adherence clubs in particular.
Fig. 5 Proportion of participants with controlled Blood Pressure (BP) 
at three time points
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This study had several notable findings. Firstly, adher-
ence to group visits (club attendance) was high and 
sustained at 1-year of attending IC. At 1-year post IC reg-
istration, 93.1% of our population was retained in care. 
While 6.9% of PLHIV were lost to follow up in our study, 
they may have continued to receive care at an alternative 
clinic, as is common in this setting.
Secondly, HIV control was sustained at 1-year post 
IC enrolment with optimal viral suppression near 100%. 
This finding is reassuring as observed viral suppres-
sion, adherence and retention rates are similar to those 
reported in ordinary MACs in this setting [14, 31, 32]. 
This demonstrates good progress towards the UNAIDS 
90:90:90 targets for HIV epidemic control (at least 90% 
of PLHIV receiving ART should have suppressed viral 
loads) [33]. In addition, this finding demonstrates that 
NCD care can be safely incorporated into HIV care pro-
grams without compromising HIV care, thus supporting 
the notion of leveraging HIV infrastructure for NCD care 
in the context of the rising NCD epidemic among PLHIV. 
In addition to increased efficiency in terms of optimizing 
utilization of resources, the integration of HIV and NCD 
care has also been reported to be convenient and accept-
able to patients [34].
Thirdly, low NCD control rates were found before IC 
enrolment with an increase in proportion of participants 
with optimal control at IC enrolment (most likely due to 
the fact that control of comorbidities was a requirement 
for eligibility for IC enrolment) but a decline in optimal 
control at 1-year post IC enrolment was observed. The 
reason for this decline post IC enrolment is unclear. One 
possible reason is insufficient exposure to regular NCD-
specific health promotion counselling after IC enrolment 
and thus a lack of support for behaviour modification 
post IC enrolment. Patients may also have been moti-
vated to adhere to NCD counselling advice prior to IC 
in order to become eligible for IC enrolment and benefit 
from the additional conveniences of IC one of which is 
reduced waiting time at the facility. The absence of sus-
tained NCD health promotion in IC clinics to support 
maintenance of positive behaviour changes, may have 
removed the necessary reinforcement required to main-
tain disease control after enrolment into IC. As NCD 
control is not simply a product of medication adherence 
but also requires modification of behavioural factors such 
as diet, smoking and physical exercise, insufficient sup-
port (for example for healthy food security) for modifi-
cation of such behaviours may have contributed to the 
lapse in NCD control post IC enrolment [35–37]. Simi-
larly, unmeasured health system factors such as changes 
to health personnel or other aspects of service delivery in 
the period post IC enrolment could also have potentially 
negatively affected NCD control.
Three variables at baseline were associated with control 
of NCD after 12 months of attending IC. These are: WHO 
stage at base line, time with NCD and facility. Clinic A 
was associated with better NCD control compared to 
Table 3 Baseline characteristics associated with control of NCD
Bold p values indicated statitistical significance
Base line characteristic Controlled NCD N(%) p value
Age category
 < 40 16 (19.8)
 40–50 38 (46.9)
 > 50 27 (33.3) 0.974
Sex
 Male 25 (30.9)
 Female 56 (69.1) 0.072
NCD
 DM only 2 (2.5)
 HTN only 74 (91.4)
 HTN and DM 5 (6.2) 0.430
BMI
 < 18.5 0 (0)
 18.5–< 25 9 (20.9)
 25–< 30 9 (20.9 0.654
 > 30 25 (58.1)
WHO stage
 0 25 (30.9)
 1 21 (25.9)
 2 26 (32.1)
 3 3 (3.7)
 4 6 (7.4) 0.012
CD4 count category
 < 350 35 (61.4)
 > 350 22 (38.6) 0.404
Duration on ART 
 0–5 59 (72.8)
 6–10 22 (27.2)
 > 10 0 (0) 0.486
Duration with HIV
 0–5 37 (58.7)
 6–10 18 (28.6)
 > 10 8 (12.7) 0.537
Duration with NCD
 0–5 36 (72)
 6–10 13 (26.0)
 > 10 1 (2.0) 0.004
Good adherence
 No 4 (4.94)
 Yes 77 (95.1) 0.204
Facility
 A 33 (40.7)
 B 48 (59.6) 0.004
Page 10 of 13Gausi et al. AIDS Res Ther           (2021) 18:72 
Table 4 Factors associated with NCD control at 12 months post IC enrolment
DM Diabetes mellitus, HTN Hypertension, DMHTN Dual diagnosis of hypertension and diabetes mellitus
a OR = unadjusted odds ratio
b aOR = adjusted odds ratio, p values in bold significant at α = 0.2 level
Bold p values indicated statitistical significance
Characteristic Univariate analyses Multivariate analyses
ORa 95% CI p-value aORb 95% CI p-value
CD4 count at HIV diagnosis (cells/µL)
 < 350 1.00 1.00
 ≥ 350 0.67 (0.35, 1.27) 0.217 0.59 (0.29, 1.18) 0.138
Time since NCD diagnosis (years)
 0–5 1.00 1.00
 6–10 0.27 (0.09, 0.83) 0.022 0.35 (0.10, 1.16) 0.087
 > 10 0.68 (0.12, 3.79) 0.656 1.42 (0.22, 9.25) 0.716
Good adherence (> 80%)
 No 1.00 1.00
 Yes 0.47 (0.19, 1.19) 0.112 0.47 (0.16, 1.38) 0.17
Clinic site
 Clinic A 1.00
 Clinic B 1.56 (0.85, 2.87) 0.150 1.50 (0.71, 3.16) 0.284
Age group (years)
 < 40 1.00




 Female 1.09 (0.58, 2.03) 0.794
Comorbidity
 DM 1.00
 DMHTN 0.46 (0.06, 3.36) 0.447
 HTN 1.00 (0.12, 8.42) 1
BMI category
 < 18.5 1.00
 18.5–24.9 0.47 (0.026, 8.52) 0.610
 25.0–29.9 0.89 (0.05, 15.44) 0.939
 ≥ 30 0.54 (0.032, 8.90) 0.666
WHO stage at HIV diagnosis
 0 1.00
 1 0.78 (0.39, 1.56) 0.483
 2 0.94 (0.48, 1.87) 0.866
 3 2.03 (0.76, 5.41) 0.157
 4
Time on ART (years)
 0–5 1.00
 6–10 0.96 (0.51, 1.79) 0.896
 > 10 1.97 (0.12, 31.99) 0.634
Time since HIV diagnosis (years)
 0–5 1.00
 6–10 1.26 (0.69, 2.28) 0.443
 > 10 1.23 (0.51, 2.96) 0.637
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clinic B. This could be due to presence of enabling health 
system factors at clinic A not available at clinic B such as 
well-trained club facilitators. Contrary to common sense, 
this study found out that patients who had a more recent 
diagnosis of NCD controlled their NCD better than the 
so called “veterans” who had been diagnosed with NCD 
a little earlier before club enrolment. The idea of “vet-
erans” getting “used to their diagnosis’ may explain this 
phenomenon. The association of WHO stage with NCD 
control may be due to the fact that people diagnosed 
with HIV at earlier stages may have been more physi-
cally capable to adopt healthier life -styles such as physi-
cal exercise compared to sicker patient presenting in later 
WHO stages. Therefore, from this finding, people start-
ing clubs in later WHO stages and those presenting with 
‘old” NCD at base line may need more support to pro-
mote NCD control.
The high proportion of patients with poor NCD, 
particularly DM, control 12  months before IC enrol-
ment, highlights the burden of poorly controlled NCDs 
among PLHIV receiving vertical, non-integrated care. 
This has a negative impact on quality of life for PLHIV 
as it increases risk of vascular events such as stroke and 
microvascular events such as renal and ophthalmic dis-
ease in addition to ART and HIV complications, thereby 
exacerbating mortality and morbidity among PLHIV. 
The higher rates of NCD control at IC enrolment in our 
study population show the potential of streamlined and 
intensified care in achieving greater NCD control among 
PLHIV with MM.
The proportion of participants with optimal BP and 
glycaemic control 1-year post IC attendance in our study 
are comparable to those found by Oluwatoyin et al. [23] 
who described clinical outcomes among PLHIV with 
comorbid NCD in the USA attending a similar model of 
integrated care(model iv). In that study, approximately 
50% of PLHIV with comorbid DM were reported to have 
achieved glycaemic control and 47% of PLHIV with HTN 
were reported to have achieved BP control. Rates of NCD 
control in our study are also consistent with findings 
from a study in Uganda that described NCD outcomes 
among patients upon simultaneous integration of HIV 
and NCD services at a health facility (model iii) in which 
a BP control rate of 46% was achieved after attending 
integrated care for 3 years[21]. Of note, our NCD control 
rates are considerably higher (by 20% in HTN and 10% in 
DM) than NCD control rates reported among HIV-nega-
tive patients also receiving care at public primary health 
care facilities in the same Cape Town setting where 33% 
and 42% of patients with HTN and DM were reported to 
have optimally controlled BP and diabetes respectively 
[38]. This may be due to increased access to adherence 
counselling and retention support that PLHIV received 
compared to their HIV- negative counterparts as was 
observed in a Ugandan study by Kwarisiima et al. [21].
Our study had several limitations. Socioeconomic vari-
ables known to independently affect HTN and DM con-
trol such as income, level of education and behavioural 
factors (smoking, diet and exercise) [39, 40] were not 
available from routinely collected patient data and hence 
were not included in data collection and analysis. As 
a result, we do not know the impact of these factors on 
NCD outcomes in our study population. A single blood 
pressure measurement, recorded in medical folders, was 
used to assess control 12 months after IC enrolment. This 
may not sufficiently capture the extent of clinical control 
for patients with hypertension. We also acknowledge the 
fact that by 12 months post IC enrolment, almost 7% of 
patients were lost to follow up(6.9%). In addition, among 
the patients still in care at 12  months, the proportion 
that had a measured viral load, blood pressure or HbA1c 
varied from 66–85% (Fig. 1). This could have resulted in 
retention bias if patients with worse NCD outcomes were 
less likely to be lost to follow up or were more likely to 
have a measured test of disease control recorded. How-
ever, evidence from previous studies that have demon-
strated that patients lost to follow up are less likely to 
be adherent to medication [41–43] make this unlikely. 
Furthermore, a proxy for adherence was used which may 
not correctly capture true adherence and its impact on 
NCD control since medication collection may be a nec-
essary but not sufficient factor for medication adherence. 
We therefore recommend future studies to assess NCD 
clinical outcomes such as blood pressure at multiple time 
points and well -designed prospective cohort studies to 
minimize measurement error and potential bias due to 
attrition.
Lastly, while univariate logistic regression analyses 
showed that time with NCD, adherence status and clinic 
site at IC enrolment were associated with control of NCD 
at 1-year post IC enrolment, multivariate analysis did 
not reveal any statistically significant associations. This 
could be partly due to the small sample size resulting into 
low statistical power in our multivariate logistic model. 
However, as we included the entire population of eligi-
ble participants without sampling, numbers were ulti-
mately restricted by the low total number of patients to 
begin with attending IC clinics at the time the study was 
conducted.
Conclusion
Our study demonstrated that adults with HIV/NCD 
multimorbidity can sustain high levels of HIV control 
following enrolment into integrated NCD and ART 
care as evidenced by high levels of adherence, viral sup-
pression and minimal loss to follow-up. This evidence 
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supports the move towards integration of NCD care 
into routine HIV care, leveraging pre-existing HIV 
infrastructure for NCD care, particularly in high HIV-
burden settings undergoing rapid epidemiological tran-
sition with a rise in NCD burden and MM. However, 
we note that NCD control was suboptimal. Therefore, 
intensified NCD-specific health promoting interven-
tions, upon enrolment into integrated care are needed, 
particularly for patients with advanced HIV disease or 
a long NCD history, to sustain NCD control in the long 
term.
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